Interact live with Dr. Foran and submit your questions regarding the status
of clinical trials in Florida for patients with AML.
Program Overview
Prognosis is dramatically reduced for AML patients undergoing allo-HSCT with active leukemia; therefore, an effective salvage chemotherapy is essential in refractory or relapsed disease. However, faced with cumulative toxicity and worsened prognosis, this is only feasible for patients in good condition. Innovative new approaches with more active and less toxic therapeutic agents are urgently needed for older patients with AML in order to more effectively stabilize remissions and successfully bridge to transplant. Clinical trials play a key role in providing such options. In this activity. Dr. James Foran will discuss the best ways to bridge older patients to transplant, including which clinical trials may be good options.
Target Audience
This activity is designed for multidisciplinary healthcare providers including hematologists, oncologists, nurses, and other allied healthcare professionals who provide medical care to patients with acute myeloid leukemia.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Address clinician- and patient-specific barriers to transplantation in older patients with relapsed or refractory AML
- Utilize appropriate strategies for bridging older patients with relapsed or refractory AML to transplant after discussing the risks and benefits with older patients and their families
- Refer appropriate older patients residing in Florida to geographically available clinical trials evaluating bridging strategies from relapsed or refractory AML to transplant, providing information and resources that address specific concerns about trial participation
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Faculty Disclosures
Dr. James Foran has received honoraria as a consultant for Revolution Medicines, Inc. and honoraria related to formal advisory activities from Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc. and SERVIER. His institution has received grant support related to research activities from AbbVie Inc., Actinium Pharmaceuticals, Inc., Aprea Therapeutics, Aptose Biosciences, Boehringer Ingelheim GmbH, H3 Biomedicine Inc., Kura Oncology, Inc., Takeda Oncology, Trillium Therapeutics Inc., and Xencor.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Instructions for Participation and Credit
There are no fees for participating in this activity.
In order to receive credit, all participants must complete the self-assessment post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.
Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.
If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or [email protected].
Supported by an educational grant from Actinium Pharmaceuticals.
